Omeros Corporation (OMER) stock reached a 52-week high of $19.75, trading at $19.87 on Tuesday — just one percent below its peak — as the biotech company rides a wave of strong second-quarter earnings and growing momentum from its newly approved drug, Yartemlea.
The company reported adjusted earnings of $0.02 per share for the quarter, easily surpassing analysts' expectations of a $0.25 per share loss. Revenue came in at $28.5 million, more than doubling the $12.67 million forecast, driven largely by commercial uptake of Yartemlea since its recent approval.
Cantor Fitzgerald upgraded its rating on the stock from Neutral to Overweight, setting a price target of $22.00 — nearly 11 percent above current levels. The upgrade adds weight to the stock's recent surge; Omeros shares are up more than 332 percent over the trailing year.
The stock's annual gains have come with elevated volatility. Omeros carries a beta of 2.6, meaning it tends to swing roughly two-and-a-half times wider than the broader market. At a market capitalization of $1.34 billion and a forward price-to-earnings ratio of 12.49, some analysts see limited room for further rerating.
InvestingPro flagged the shares as overvalued relative to its internal fair-value estimate, cautioning that the dramatic rally may have priced in more upside than fundamentals currently support. The firm pointed to the gap between the stock's market price and its model-derived value as a warning sign for new entrants.
Despite the valuation headwinds, Wall Street appears increasingly bullish. The combination of a successful product launch, a sharp turnaround from projected losses to positive earnings, and an analyst upgrade has shifted sentiment around the small-cap biotech — at least for now.
